PIK3CA and breast carcinoma: Specifically, mutations in PIK3CA resulted in poor outcomes in metastatic breast cancer patients and resistance to chemotherapy [4]; the loss of PIK3CA suppressed cancer cell growth and migration in malignancies [8,22].